{"id":"de-111-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DE-111 works by stimulating dopamine D1 receptors in the eye, which promotes increased drainage of fluid (aqueous humor) through the trabecular meshwork and uveoscleral pathways. This enhanced outflow reduces intraocular pressure, the primary pathogenic factor in glaucoma. The dopamine D1 agonist mechanism represents a novel approach distinct from traditional prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors.","oneSentence":"DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:52.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension"}]},"trialDetails":[{"nctId":"NCT01342094","phase":"PHASE3","title":"DE-111 Against Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":166},{"nctId":"NCT01343082","phase":"PHASE3","title":"DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":148},{"nctId":"NCT01342081","phase":"PHASE3","title":"DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":489}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DE-111 ophthalmic solution","genericName":"DE-111 ophthalmic solution","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma. Used for Glaucoma or ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}